In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on Cullinan Management, with a price target of $34.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Soumit Roy has given his Buy rating due to a combination of factors that highlight Cullinan Management’s potential for growth and value. Despite the delay in the systemic lupus erythematosus (SLE) trial data to the first half of 2026, the company remains poised for significant developments with upcoming data releases in lung cancer and acute myeloid leukemia (AML) expected in the fourth quarter of 2025. The delay in the SLE trial is attributed to slow patient enrollment, not adverse events, and the company is actively working to broaden eligibility criteria to accelerate this process.
Additionally, Cullinan’s pipeline includes promising programs such as the EGFR inhibitor for non-small cell lung cancer and the FLT3xCD3 T-cell engager for AML, which are anticipated to provide crucial data soon. The company’s strategic amendments to the SLE trial and ongoing efforts in rheumatoid arthritis research further bolster its potential. With a solid cash position and a focus on advancing its clinical programs, Cullinan Management presents a compelling investment opportunity, justifying the Buy rating.
In another report released on August 21, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $24.00 price target.